Abstract:
A color adjustment interface includes an original image thumbnail representing a version of an image prior to modification, a current image thumbnail representing a version of an image after a modification and a color polygon including a multitude of variation image thumbnails each representing a color variation. Each selection of a variation image thumbnail modifies the current image thumbnail in an adjustment towards a color represented by the selected variation image.
Abstract:
Methods, systems, and media to enhance image processing for a color reprographic system are disclosed. Embodiments of the invention may calibrate a component like scanner and/or printer in response to user input and/or coupling the component to the reprographic system. More specifically, embodiments may generate correction parameters that describe differences in color values between an image scanned by a scanner or an image printed by the printer by comparing the outputs to known characteristics like color values for the image. Some embodiments comprise a graphical user interface (GUI) to communicate with the user, allowing the user to select user preferences to change, for example, the brightness of an image being copied. Further embodiments incorporate network and phone system interfaces to communicate with remote components as well as to receive input from and/or output to other systems via email, facsimile, etc.
Abstract:
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
Abstract translation:具有式I结构的化合物,包括化合物的药学上可接受的盐,是CETP抑制剂,可用于升高HDL-胆固醇,降低LDL-胆固醇,以及用于治疗或预防动脉粥样硬化。在式I化合物中,B或 R 2是具有邻芳基,杂环,苯并杂环或苯并环烷基取代基的苯基,并且在5元环上的另一个位置具有直接连接的芳族,杂环,环烷基,苯并杂环或苯并环烷基取代基 通过-CH 2 - 2连接到环上或连接到环上。
Abstract:
A method for breathing of scheduling algorithms for a storage device (110). The method including: (a) computing a worst-case duration of a breathing cycle (P) for the storage device (110); (b) starting a breathing cycle; (c) determining if one of the following becomes true before the end of P: (i) a number of real-time requests is at least a predetermined threshold based on a number of data streams and performance parameters of the storage device; and (ii) a number of pending requests for any single stream becomes more than one; (d) if at least one of (i) and (ii) remain true during the duration of P, starting a subsequent breathing cycle after completion of the breathing cycle; and (e) if both of (i) and (ii) are not true during the duration of P, waiting P time units from the start of the breathing cycle before starting the subsequent breathing cycle.
Abstract:
Provided are techniques for transferring data. It is determined whether an indicators map is to be associated with a source file that is being opened, wherein the indicators map indicates which source blocks of the source file have been updated since last being transferred to a target file. In response to determining that an indicators map is to be associated with the source file, it is determined whether the indicators map exists. In response to determining that the indicators map exists, it is determined whether the indicators map is to be trusted based on a last modified time and a last source file size stored in the indicators map and the source file. In response to determining that the indicators map is to be trusted, the indicators map is initialized. Then, in response to receiving a write for the source file, the indicators map is updated to indicate which portion of the source file has been modified.
Abstract:
A method and apparatus for using a secondary refrigerant to precool and liquefy a primary refrigerant, then vaporizing and expanding the primary refrigerant to cool a cold tip of a cryosurgical instrument for ablation of biological tissue, such as cardiovascular tissue, in particular endocardiac tissue and tissue inside a cardiac blood vessel. The secondary refrigerant has a critical temperature above the critical temperature of the primary refrigerant, and a cooling temperature below the critical temperature of the primary refrigerant, thereby facilitating the use of the precooling step to provide liquid primary refrigerant in an operating room environment in which the primary refrigerant could not otherwise be provided in the liquid phase.
Abstract:
Non-contiguous storage of data objects seriously hampers retrieval speed of said data objects (202). Furthermore, when multiple data objects are retrieved of which some are fragmented, retrieval time of all data objects gets less predictable. Therefore, it is desirable to retrieve non-fragmented data objects only. For certain cases, this is possible, as not necessarily one specific data object has to be retrieved. In such cases, retrieval of a similar data object, render of the same type, is sufficient. To this, the invention provides among others a method and circuit (124) for retrieval of data. The invention is especially suitable for retrieving audiovisual data for trickplay. When a first frame selected for rendering is stored fragmented, a second, not fragmented frame is selected and retrieved instead of the first frame.
Abstract:
The present invention provides biodegradable polymer particle delivery compositions for delivery of macromolecular biologics, for example in crystal form, based on polymers, such as polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers, which contain amino acids in the polymer. The polymer particle delivery compositions can be formulated either as a liquid dispersion or a lyophilized powder of polymer particles containing bound water molecules with the macromolecular biologics, for example insulin, dispersed in the particles. Bioactive agents, such as drugs, polypeptides, and polynucleotides can also be delivered by using particles sized for local, oral, mucosal or circulatory delivery. Methods of delivering a macromolecular biologic with substantial native activity to a subject, for example orally, are also included.
Abstract:
The present invention provides an implantable solid polymer delivery composition that can be formulated to release a bioactive agent to an interior body site at a controlled rate over an extended period of time by adjusting the various components of the composition. The controlled delivery of the composition avoids an initial drug spike, resulting in a smooth delivery profile over time. Polymer layers in the composition can be porous and are both biodegradable in water and body enzymes and biocompatible. Methods of making the implantable solid polymer compositions and methods of delivering a bioactive agent at a controlled rate to an interior body site are also provided.
Abstract:
A method is provided for enabling to establish a connection between multiple UpnP-compliant resources, wherein each of the resources has a respective ConnectionManager service. The method comprises configuring the respective ConnectionManager services so to enable a UpnP Control Point to use the respective services for negotiating the connection between the respective resources to be established at a time determined in advance.